



Efficacy of epicutaneous immunotherapy (EPIT) in a new model of peanut-induced eosinophilic esophagitis (EoE) and allergic enteropathy (AE)

Lucie Mondoulet, Vincent Dioszeghy, Véronique Dhelft, Mélanie Ligouis,
Emilie Puteaux, Thibaut T. Larcher, Yan Cherel, Christophe Dupont,
Pierre-Henri Benhamou

► To cite this version:

Lucie Mondoulet, Vincent Dioszeghy, Véronique Dhelft, Mélanie Ligouis, Emilie Puteaux, et al.. Efficacy of epicutaneous immunotherapy (EPIT) in a new model of peanut-induced eosinophilic esophagitis (EoE) and allergic enteropathy (AE). Food Allergy and Anaphylaxis Meeting, Feb 2011, Venice, Italy.
hal-02747086

HAL Id: hal-02747086

<https://hal.inrae.fr/hal-02747086>

Submitted on 3 Jun 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



ORAL PRESENTATION

Open Access

Efficacy of epicutaneous immunotherapy (EPIT) in a new model of peanut-induced eosinophilic esophagitis (EoE) and allergic enteropathy (AE)

Lucie Mondulet^{1*}, Vincent Dioszeghy¹, Véronique Dhelft¹, Mélanie Ligouis¹, Emilie Puteaux¹, Thibaut Larcher², Yan Cherel², Christophe Dupont³, Pierre-Henri Benhamou¹

From Food Allergy and Anaphylaxis Meeting 2011
Venice, Italy. 17-19 February 2011

Background

Eosinophilia is often linked to allergic gastrointestinal disorders linked to food allergy. EPIT using Viaskin® device has been described as a therapeutic method in food allergy. We developed a model of mice sensitized to peanut, exhibiting EoE and AE after exclusive feeding with peanut protein extracts (PPE). This study was conducted in order to evaluate the efficacy of EPIT.

Methods

After oral sensitization with PPE and cholera toxin, 30 BALB/c mice were treated weekly during 8 weeks by PPE skin applications (EPIT), 20 mice were not treated (Sham) and 10 mice constituted the control group (C). Mice were then exclusively fed with PPE. Specific IgE, IgG1 and IgG2a were monitored during immunotherapy. Esophageal and jejunal samples were taken for histological analyses.

Results

sIgE increased after oral sensitization, respectively 0.207 ± 0.03 and 0.214 ± 0.04 µg/ml, in EPIT and Sham, with undetectable values in C. Following EPIT, sIgE decreased and sIgG2a increased, respectively 0.139 ± 0.01 vs 0.166 ± 0.01 µg/ml (EPIT vs Sham, p<0.05) and 14.96 ± 0.60 vs 4.73 ± 1.75 µg/ml (p<0.05). Esophageal eosinophilic infiltration (measured in 6 high power fields) was higher in Sham, 136 ± 32 , than in EPIT, 50 ± 12 (p<0.05) and C, 7 ± 3 cells/mm² (p<0.01). Esophagus mucosa thickness was increased in Sham compared to EPIT and C (p<0.001). Sham group exhibited higher mRNA levels

of cytokines than EPIT: eotaxin (p<0.05), IL-5 (p<0.05), IL-13 (p<0.05). The mRNA levels of these cytokines in EPIT were similar to C. The expression of Foxp3 mRNA increased significantly after EPIT compared with Sham and C (p<0.05). The jejunal villus/crypt ratio was lower in Sham than in EPIT and C, respectively 1.6 ± 0.1 vs 2.3 ± 0.2 (p<0.01) and 2.4 ± 0.1 (p<0.001). Eosinophilic infiltration in jejunum was increased in Sham compared to EPIT (p<0.01) and C (p<0.001).

Conclusion

EPIT is effective in preventing EoE and AE induced by oral challenge in mice sensitized to peanut.

Author details

¹DBV Technologies, Paris, France. ²APEX, INRA, Nantes, France. ³Hôpital Saint Vincent de Paul, Paris, France.

Published: 12 August 2011

doi:10.1186/2045-7022-1-S1-O50

Cite this article as: Mondulet et al.: Efficacy of epicutaneous immunotherapy (EPIT) in a new model of peanut-induced eosinophilic esophagitis (EoE) and allergic enteropathy (AE). *Clinical and Translational Allergy* 2011 **1**(Suppl 1):O50.

¹DBV Technologies, Paris, France

Full list of author information is available at the end of the article